MedRhythms and EVERSANA Announce Partnership: To Launch and Commercialize Chronic Stroke Software-based Medical Device
MedRhythms, a Portland, Maine-based digital therapeutics company that is building direct stimulation, prescription digital therapeutics that use sensors, music, and software to improve walking...
Clarius Introduces First Ultrasound System That Uses AI and Machine Learning to Recognize Anatomy for an Instant Window into the Body
"Although machine learning and artificial intelligence have been applied to medical imaging over the past several years, this is the first commercially available application that enables an ultrasound system to recognize anatomy on a macro level, allowing the AI to recognize different structures in the human torso," says Kris Dickie, Vice President of Research and Development at Clarius
Imbio and Riverain Technologies Partner to Offer a Comprehensive AI-Powered Lung Health Solution
Together, Riverain and Imbio are one step closer to providing the complete quantitative imaging solution that healthcare institutions and their treating physicians have requested and need to support their Lung Cancer Screening and their entire Lung Health programs.
Boston Scientific: Late-breaking EuroPCR Data Demonstrate Positive Outcomes with BSX ACURATE neo2 valve
"These real-world findings reinforce the effectiveness of the ACURATE neo2 valve design enhancements –including the 60% larger outer sealing skirt to conform to challenging anatomies – that have minimized PVL and shown excellent clinical outcomes in a broad spectrum of patients when compared to data collected with the previous-generation ACURATE neo™ Aortic Valve System," said Dr. Ian Meredith, global chief medical officer, Boston Scientific.
Evolut TAVR System Shows Strong Performance at 2 Years in Low Risk Trial
Presented virtually today as a late-breaking clinical trial at the EuroPCR 2021 e-Course, results showed the Evolut TAVR platform was non inferior to surgery for the primary endpoint of all-cause mortality or disabling stroke at two years (4.3% for TAVR versus 6.3% for surgery; p< 0.0001 for non-inferiority), and trended the same or lower on all critical events, confirming the earlier Bayesian statistical analysis presented at the American College of Cardiology (ACC) 68th Annual Scientific Session in 2019.